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Varenicline may induce psychotic
symptoms in subjects without previous
history of psychiatric disorders
Varenicline is a partial agonist of the α4β2
nicotinic acetylcholine receptor, which has
recently been introduced as a treatment for
smoking cessation. It is increasingly
prescribed by psychiatrists and general
practitioners (GPs). Several cases, though,
have been reported of varenicline leading
to exacerbations of psychotic symptoms in
patients with psychiatric antecedents
(1–4). We report what is to our
knowledge the first case of psychotogenic
effects of varenicline in a female patient
with no psychiatric history.
Mrs A, a healthy 42-year-old female
nurse with no psychiatric history, who had
smoked an average of 30 cigarettes/day
since age 18, consulted her GP requesting
medical assistance for smoking cessation.
After informed consent, she was
prescribed varenicline, 0.5 mg/day for the
first 3 days, then, 0.5 mg/day up to the 7th
day, and 1.0 mg/day thereafter. During the
first 3 days, the patient experienced
increased and vivid dreaming. She
especially reported remembering much
more from her dreams than she was used
to. Concerning smoking, she reported
having effortlessly reduced her
consumption down to 3 cigarettes/day.
Subsequent to the dose increase from
day 4 to 7 she experienced a significant
mood worsening, as well as concentration
difficulties. She reported significant mood
labilities eventually leading to domestic
conflicts with her partner. Additionally she
found herself struggling with usually easy
tasks (e.g. picking up children from
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school), and increasingly suffered from
muscular and articular pains upon waking.
In the afternoon of the 9th day (i.e.
1 day after dose augmentation to 1 mg
b.i.d.), she complained about highly
distressing visual hallucination (insects
moving around on the ground), which she
had never experienced in the past, and
which persisted for more than 3 h. In
agreement with her GP, it was therefore
decided to discontinue the treatment.
For subsequent nights she again
reported periods of increased and vivid
dreaming. However, no further
hallucinations appeared. Also, the mood
alterations gradually faded over the next
week. Five days after varenicline
cessation, she relapsed to smoking
1 packet/day.
Six months later, and in accordance
with her GP, she retook a varenicline
treatment, using the same treatment
protocol. Once again, varenicline had to be
discontinued at the end of the 4th day
because of the reappearance of negative
mood and the patient fearing the
re-emergence of hallucinations.
This is to our knowledge the first report
of psychotogenic effects of varenicline in
a patient with no psychiatric history.
While a simple withdrawal phenomenon
independent from varenicline cannot be
ruled out, it seems less likely, as
hallucinations not being part of a usual
nicotine withdrawal. One open question
remains about the correlation between
increased dreaming activity and
hallucinations. Increasing dreaming has
been reported for nicotine withdrawal (5).
As the presented patient had experienced
previous nicotine withdrawals without the
symptoms described in the present report,
a correlation with varenicline seems more
probable.
In conclusion, while varenicline
represents an interesting new therapeutic
alternative in the treatment of nicotine
dependence, caution is warranted
regarding the appearance of psychotic
symptoms not only in patients with a
history of psychosis.
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